Botanical Solution, a Davis, CA-based advanced botanical materials company, raised additional $7M in Series A funding.
The round, which brought the total amount to over $13M, was led by Otter Capital, with participation from Latin American investors Boldo SpA and Quebec LP controlled by the Casanueva and Saval family offices.
The company intends to use the funds to scale up the GMP production of the vaccine adjuvant, QS-21, and fulfill the supply agreements with Croda and other Big Pharma companies.
Led by CEO Gaston Salinas, Botanical Solution leverages a proprietary platform to improve production of consistent advanced botanical materials (ABM). ABM-01 is the first ABM produced by the company, based on a plant called Quillaja saponaria. It is the active ingredient used in two standard products, BSI’s biopesticide Quillibrium® and the vaccine adjuvant QS-21, used in a Shingles blockbuster vaccine, a recently launched RSV vaccine and a Malaria vaccine.
The new investment enables the company to develop a sustainable supply chain for the gold standard vaccine adjuvant QS-21, and boosts the expansion plan for agriculture, which includes the roll out of BSI’s flagship product Quillibrium® in Mexico, Brazil, the US and EU. The partnership with Syngenta established since 2019 has produced over 50% YOY growth of effective growers’ adoption of the product in Chile and Peru, accumulating over 100,000 acres treated to date.
FinSMEs
24/08/2023